Line by Line: Distinct Patterns of Anti-EGFR Antibody Resistance by Line of Therapy

Corcoran, Ryan B.

doi:10.1200/jco.22.01922

Cited by 3 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To clarify the role of the PI3K/Akt/mTOR pathway in chemoresistance of HNSCC patients, we should refer to the importance of epidermal growth factor receptor (EGFR) (Cohen, 2014; Kalyankrishna & Grandis, 2006; Kriegs et al, 2019), which takes part in the regulation of host cellular processes including cell proliferation, differentiation, and migration. Multiple studies and clinical investigations have shown the promising targeting of EGFR and ErbB family in the treatment of HNSCC (Cohen, 2014; Corcoran, 2023). Cetuximab, which acts as an anti‐EGFR targeted drug, is approved for HNSCC cancer (Adkins et al, 2019; Niu et al, 2010).…”

Section: Introductionmentioning

confidence: 99%

Exploiting new strategies in combating head and neck carcinoma: A comprehensive review on phytochemical approaches passing through PI3K/Akt/mTOR signaling pathway

Iranpanah,

Majnooni,

Biganeh

et al. 2024

Phytotherapy Research

View full text Add to dashboard Cite

Recently, malignant neoplasms have growingly caused human morbidity and mortality. Head and neck cancer (HNC) constitutes a substantial group of malignancies occurring in various anatomical regions of the head and neck, including lips, mouth, throat, larynx, nose, sinuses, oropharynx, hypopharynx, nasopharynx, and salivary glands. The present study addresses the phosphoinositide 3‐kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) pathway as a possible therapeutic target in cancer therapy. Finding new multitargeting agents capable of modulating PI3K/Akt/mTOR and cross‐linked mediators could be viewed as an effective strategy in combating HNC. Recent studies have introduced phytochemicals as multitargeting agents and rich sources for finding and developing new therapeutic agents. Phytochemicals have exhibited immense anticancer effects, including targeting different stages of HNC through the modulation of several signaling pathways. Moreover, phenolic/polyphenolic compounds, alkaloids, terpenes/terpenoids, and other secondary metabolites have demonstrated promising anticancer activities because of their diverse pharmacological and biological properties like antiproliferative, antineoplastic, antioxidant, and anti‐inflammatory activities. The current review is mainly focused on new therapeutic strategies for HNC passing through the PI3K/Akt/mTOR pathway as new strategies in combating HNC.

show abstract

Section: Introductionmentioning

confidence: 99%

Exploiting new strategies in combating head and neck carcinoma: A comprehensive review on phytochemical approaches passing through PI3K/Akt/mTOR signaling pathway

Iranpanah,

Majnooni,

Biganeh

et al. 2024

Phytotherapy Research

View full text Add to dashboard Cite

show abstract

Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm

Ciracì,

Studiale,

Taravella

et al. 2024

Nat Rev Clin Oncol

View full text Add to dashboard Cite

Prognostic and predictive biomarkers with therapeutic targets in nonsmall-cell lung cancer: A 2023 update on current development, evidence, and recommendation

Chung,

Umoru

2024

J Oncol Pharm Pract

View full text Add to dashboard Cite

Background Since the publication of the original work in 2014, significant progress has been made in the characterization of genomic alterations that drive oncogenic addiction of nonsmall cell lung cancer (NSCLC) and how the immune system can leverage non-oncogenic pathways to modulate therapeutic outcomes. This update evaluates and validates the recent and emerging data for prognostic and predictive biomarkers with therapeutic targets in NSCLC. Data sources We performed a literature search from January 2015 to October 2023 using the keywords non-small cell lung cancer, clinical practice guidelines, gene mutations, genomic assay, immune cancer therapy, circulating tumor DNA, predictive and prognostic biomarkers, and targeted therapies. Study selection and data extraction We identified, reviewed, and evaluated relevant clinical trials, meta-analyses, seminal articles, and published clinical practice guidelines in the English language. Data synthesis Regulatory-approved targeted therapies include those somatic gene alterations of EGFR (“classic” mutations, exon 20 insertion, and rare EGFR mutations), ALK, ROS1, BRAF V600, RET, MET, NTRK, HER2, and KRAS G12C. Data for immunotherapy and circulating tumor DNA in next-generation sequencing are considered emerging, whereas the predictive role for PIK3CA gene mutation is insufficient. Conclusions Advances in sequencing and other genomic technologies have led to identifying novel oncogenic drivers, novel resistance mechanisms, and co-occurring mutations that characterize NSCLC, creating further therapeutic opportunities. The benefits associated with immunotherapy in the perioperative setting hold initial promise, with their long-term results awaiting.

show abstract

Line by Line: Distinct Patterns of Anti-EGFR Antibody Resistance by Line of Therapy

Cited by 3 publications

References 24 publications

Exploiting new strategies in combating head and neck carcinoma: A comprehensive review on phytochemical approaches passing through PI3K/Akt/mTOR signaling pathway

Exploiting new strategies in combating head and neck carcinoma: A comprehensive review on phytochemical approaches passing through PI3K/Akt/mTOR signaling pathway

Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm

Prognostic and predictive biomarkers with therapeutic targets in nonsmall-cell lung cancer: A 2023 update on current development, evidence, and recommendation

Contact Info

Product

Resources

About